Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Opthea Limited
Age
50–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Active subfoveal CNV lesion or juxtafoveal CNV lesion with foveal involvement that is secondary to AMD in the Study Eye.
An ETDRS BCVA score between 60 and 25 (inclusive) letters in the Study Eye.
You may not be if
Any previous treatment for neovascular AMD.
Clinically significant ocular disorders (other than neovascular AMD), which may interfere with assessment of BCVA, assessment of safety, or fundus imaging.
Any current (or history of a) social, psychological, or medical condition that precludes enrolment into the study.
Clareo Health | OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD)
